Erenumab 140 mg safely and effectively induced remission in nonopioid MOH within 6 months in individuals for whom other preventive medications had failed.
All News
Advertisement
Advertisement
FluMist is the first influenza vaccine that does not have to be given by a health care professional.
The only CGM system cleared for 1 year of use in type 1 and 2 diabetes is expected to be available in the fourth quarter of this year, the manufacturers said.
New report includes data on the safety and immunogenicity of the recently-approved PCV21 vaccine.
Your daily dose of the clinical news you may have missed.
Immune responses for both vaccines were noninferior when given at the same visit compared with separate administration among adults aged 50 years and older.
The positive pivotal phase 3 trial results showed improved lung function with neradomilast vs placebo and will support BI's US and global NDA submissions.
Your daily dose of the clinical news you may have missed.
Hypertension that is resistant or refractory to treatment increases the risk of comorbidity and cardiovascular risk. Click through this at-a-glance review of key issues.
EASD 2024: Amycretin was also found to be safe and well tolerated in adults with obesity and without diabetes.
Advertisement
AI is welcomed by US adults for streamlining the administrative complexity of getting medical care but not so much for replacing health care professionals themselves.
Your daily dose of the clinical news you may have missed.
New data shows that favorable CV health in the first trimester is associated with a 35% to 62% lower risk of HDP regardless of level of genetic risk.
Those least likely to schedule further screening mammograms had received a false-positive with recommendation for follow-up after only a short interval.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
Among those treated with lebrikizumab, more than one-third saw clear/almost clear skin at week 16; three-quarters of them maintained results at week 52 with monthly dosing.
Individuals with migraine who failed to respond to up to 4 previous migraine preventive treatments saw fewer monthly migraine and headache days after 1 infusion of Lu AG90222.
Based on its acceptance of the resubmission, FDA has assigned a PDUFA action goal date of January 31, 2025 for AXS-07.
The approval makes dupilumab available to treat uncontrolled CRSwNP in adolescents aged 12 to 17 years, expanding on the current approved range of 18 years and older.
Advertisement
Advertisement
Advertisement
